Desmopressin

Overview

Desmopressin (DDAVP®) is a synthetic analogue of vasopressin used in dogs and cats primarily for the diagnosis and treatment of central diabetes insipidus, as well as for certain bleeding disorders. It has a prolonged antidiuretic effect compared to vasopressin and lacks significant vasoconstrictive activity.

The drug can be administered via multiple routes including conjunctival, intranasal, injectable, and oral formulations, although bioavailability varies widely depending on the route. In veterinary practice, topical administration to the conjunctiva is commonly used.

Mechanism of Action (MOA): Desmopressin binds to antidiuretic hormone (ADH) receptors in the renal collecting ducts, increasing water reabsorption and reducing urine production. It also increases plasma concentrations of von Willebrand factor and factor VIII by promoting their release from endothelial cells.

Indications

Desmopressin is used in dogs and cats for disorders involving impaired water balance or specific coagulation deficiencies.

• Central diabetes insipidus (CDI): Used for both diagnosis (e.g., modified water deprivation test) and long-term management.
• Coagulopathies: Used to increase plasma levels of von Willebrand factor and factor VIII in patients with mild to moderate hemophilia A or von Willebrand disease.
• Diagnostic use: Employed in endocrine testing protocols for evaluation of water balance disorders.

Dosage (Reference)

Dog

In dogs, desmopressin dosing varies depending on indication (coagulopathy vs diabetes insipidus) and route of administration. Dose should be titrated based on clinical response.

Cat

In cats, desmopressin is primarily used for management of central diabetes insipidus, with dosing adjusted based on clinical response.

Warnings & Precautions

Desmopressin should be used with caution due to its potent antidiuretic effects and potential impact on fluid balance and coagulation parameters. Careful monitoring is required during therapy.

• Hypersensitivity: Contraindicated in patients with known hypersensitivity to desmopressin.
• Renal impairment: Avoid or use with caution in patients with moderate to severe renal dysfunction due to altered drug clearance and increased risk of fluid retention.
• Hyponatremia risk: May cause dilutional hyponatremia due to water retention; monitor serum sodium closely and adjust dose or fluid intake if needed.
• Fluid balance: Fluid restriction may be required in some patients to prevent water intoxication.
• Thrombotic risk: Use cautiously in patients predisposed to thrombotic events due to increased clotting factors.
• Ineffective indication: Not effective in nephrogenic diabetes insipidus.
• Repeated dosing: Repeated use for von Willebrand factor stimulation may result in tachyphylaxis (reduced response over time).
• Coagulopathy limitations: Not recommended in type IIB von Willebrand disease or type III disease due to lack of efficacy or risk of adverse effects.
• Specialist guidance: Use in diagnostic testing (e.g., water deprivation tests) requires appropriate clinical expertise and monitoring.

Drug Interactions

Desmopressin interactions are primarily related to altered antidiuretic response or increased risk of hyponatremia and fluid imbalance. Careful monitoring is required when used with the following agents.

• • Carbamazepine: May decrease antidiuretic response and increase risk of hyponatremia.
  • Chlorpromazine: May increase risk of hyponatremia.
  • Corticosteroids (e.g., dexamethasone, prednisolone, fludrocortisone): May increase risk of hyponatremia.
  • Heparin: May decrease antidiuretic response.
  • Loop diuretics (e.g., furosemide, torsemide): May increase risk of hyponatremia.
  • NSAIDs (e.g., carprofen, meloxicam): May increase risk of hyponatremia.
  • Opioids (e.g., morphine, buprenorphine): May increase risk of hyponatremia.
  • Oxybutynin: Associated with seizures when used concurrently (reported in humans).

Side Effects & Overdose

Side Effects

Adverse effects of desmopressin in dogs and cats are generally uncommon but are primarily related to its antidiuretic effects and alterations in fluid balance.

• • • Hyponatremia: Due to water retention; may lead to neurologic signs if severe.
    • Neurologic signs: Rapid decreases in sodium may cause nausea, vomiting, lethargy, seizures, or coma.
    • Ocular irritation: Mild irritation may occur with conjunctival administration.
    • Hypersensitivity reactions: Rare but possible.
    • Hypertension: Rarely reported; clinical significance in veterinary patients is uncertain.

Overdose

Overdose of desmopressin is typically associated with excessive antidiuretic activity and fluid retention. There is no specific antidote, and management is supportive.

• • • Water retention: Leads to dilutional hyponatremia.
    • Severe hyponatremia: May result in neurologic complications including seizures or coma.
    • Management: Reduce or discontinue dose and implement fluid restriction.
    • Monitoring: Close monitoring of serum sodium and fluid status is essential.

Key Notes

Practical clinical insights to guide effective use of desmopressin in dogs and cats:

• • • Route flexibility: Can be administered via multiple routes, but conjunctival application is often preferred in veterinary practice for ease and consistency.
    • Onset and duration: Antidiuretic effect typically begins within 1 hour, peaks within a few hours, and may last up to 24 hours.
    • Low oral bioavailability: Oral formulations are less reliable due to degradation in the gastrointestinal tract.
    • Individual dose titration: Significant variation exists between patients; dosing must be tailored to clinical response.
    • Monitoring response: Clinical effectiveness is assessed by reduction in water intake and urine output rather than fixed dosing.
    • Specialist protocols: Use in diagnostic testing (e.g., modified water deprivation test) requires careful planning and supervision.